Approval · Notice of Compliance 13249 · 2012
EMEND IV: Notice of Compliance 13249
Issued April 30, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13249
- Date
- April 30, 2012
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: Prevention of nausea and vomiting in women du to treatment with moderately emetogenic cancer chemotherapy
- Therapeutic class
- Neurikinin 1 (NK1) Receptor Antagonist
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EMEND IV | Not yet assigned | — |
Medicinal ingredients
- FOSAPREPITANT DIMEGLUMINE 150 MG per VIAL